Federal Register / Vol. 90, No. 6 / Friday, January 10, 2025 / Notices 2009 

Advisory Committee (the Committee). 

The Committee is a discretionary 

Federal advisory committee established 

to provide advice to the Commissioner. 

The Committee advises the 

Commissioner or designee in 

discharging responsibilities as they 

relate to helping to ensure safe and 

effective drugs for human use and, as 

required, any other product for which 

FDA has regulatory responsibility. 

The Committee reviews and evaluates 

available data concerning the safety and 

effectiveness of marketed and 

investigational human drug products for 

use in the treatment of infectious 

diseases and disorders and makes 

appropriate recommendations to the 

Commissioner of Food and Drugs. 

Pursuant to its charter, the Committee 

shall consist of a core of 13 voting 

members including the Chair. Members 

and the Chair are selected by the 

Commissioner or designee from among 

authorities knowledgeable in the fields 

of infectious disease, internal medicine, 

microbiology, pediatrics, epidemiology 

or statistics, and related specialties. 

Members will be invited to serve for 

overlapping terms of up to 4 years. NonFederal members of this committee will 

serve as Special Government Employees 

or representatives. Federal members 

will serve as Regular Government 

Employees or Ex-Officios. The core of 

voting members may include one 

technically qualified member, selected 

by the Commissioner or designee, who 

is identified with consumer interests 

and is recommended by either a 

consortium of consumer-oriented 

organizations or other interested 

persons. In addition to the voting 

members, the Committee may include 

one non-voting representative member 

who is identified with industry 

interests. There may also be an alternate 

industry representative. 

The Commissioner or designee shall 

have the authority to select members of 

other scientific and technical FDA 

advisory committees (normally not to 

exceed 10 members) to serve 

temporarily as voting members and to 

designate consultants to serve 

temporarily as voting members when: 

(1) expertise is required that is not 

available among current voting standing 

members of the Committee (when 

additional voting members are added to 

the Committee to provide needed 

expertise, a quorum will be based on the 

combined total of regular and added 

members) or (2) to comprise a quorum 

when, because of unforeseen 

circumstances, a quorum is or will be 

lacking. Because of the size of the 

Committee and the variety in the types 

of issues that it will consider, FDA may, 

in connection with a particular 

committee meeting, specify a quorum 

that is less than a majority of the current 

voting members. The Agency’s 

regulations (21 CFR 14.22(d)) authorize 

a committee charter to specify quorum 

requirements. 

If functioning as a medical device 

panel, an additional non-voting 

representative member of consumer 

interests and an additional non-voting 

representative member of industry 

interests will be included in addition to 

the voting members. 

Further information regarding the 

most recent charter and other 

information can be found at https://

www.fda.gov/advisory-committees/ 

antimicrobial-drugs-advisorycommittee-formerly-known-antiinfective-drugs-advisory-committee/ 

antimicrobial-drugs-advisorycommittee-formerly-known-antiinfective-drugs-advisory-committee or 

by contacting the Designated Federal 

Officer (see FOR FURTHER INFORMATION

CONTACT). In light of the fact that no 

change has been made to the committee 

name or description of duties, no 

amendment will be made to 21 CFR 

14.100. 

This notice is issued under the 

Federal Advisory Committee Act as 

amended (5 U.S.C. 1001 et seq.). For 

general information related to FDA 

advisory committees, please visit us at 

http://www.fda.gov/ 

AdvisoryCommittees/default.htm. 

Dated: December 31, 2024. 

P. Ritu Nalubola, 

Associate Commissioner for Policy. 

[FR Doc. 2025–00357 Filed 1–8–25; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2018–N–3233] 

Request for Nominations for Voting 

Members on a Public Advisory 

Committee; Technical Electronic 

Product Radiation Safety Standards 

Committee 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is requesting 

nominations for voting members to 

serve on the Technical Electronic 

Product Radiation Safety Standards 

Committee (TEPRSSC) in the Center for 

Devices and Radiological Health. 

Nominations will be accepted for 

current and upcoming vacancies 

effective January 1, 2025, with this 

notice. FDA seeks to include the views 

of women and men, members of all 

racial and ethnic groups, and 

individuals with and without 

disabilities on its advisory committees 

and, therefore, encourages nominations 

of appropriately qualified candidates 

from these groups. 

DATES: Nominations received on or 

before March 11, 2025, will be given 

first consideration for membership on 

TEPRSSC. Nominations received after 

March 11, 2025, will be considered for 

nomination to the committee as later 

vacancies occur. 

ADDRESSES: All nominations for 

membership should be sent 

electronically by accessing FDA’s 

Advisory Committee Membership 

Nomination Portal at https://

www.accessdata.fda.gov/scripts/ 

FACTRSPortal/FACTRS/index.cfm or by 

mail to Advisory Committee Oversight 

and Management Staff, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 32, Rm. 5103, Silver Spring, 

MD 20993–0002. Information about 

becoming a member on an FDA advisory 

committee can also be obtained by 

visiting FDA’s website at https://

www.fda.gov/AdvisoryCommittees/ 

default.htm. 

FOR FURTHER INFORMATION CONTACT: 

Akinola Awojope, Office of 

Management Services, Center for 

Devices and Radiological Health, Food 

and Drug Administration, 10903 New 

Hampshire Ave., Bldg. 66, Rm. 5216, 

Silver Spring, MD 20993–0002, 301– 

636–0512, email: Akinola.Awojope@

fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: FDA is 

requesting nominations for voting 

members on TEPRSSC that include five 

general public representatives and five 

government representatives. 

I. General Description of the 

Committee’s Duties 

The committee provides advice and 

consultation to the Commissioner of 

Food and Drugs (the Commissioner) on 

the technical feasibility, reasonableness, 

and practicability of performance 

standards for electronic products to 

control the emission of radiation from 

such products, and may recommend 

electronic product radiation safety 

standards to the Commissioner for 

consideration. 

II. Criteria for Voting Members 

The committee consists of a core of 15 

voting members including the Chair. 

Members and the Chair are selected by 


khammond on DSK9W7S144PROD with NOTICES
2010 Federal Register / Vol. 90, No. 6 / Friday, January 10, 2025 / Notices 

the Commissioner or designee from 

among authorities knowledgeable in the 

fields of science or engineering, 

applicable to electronic product 

radiation safety. Members will be 

invited to serve for overlapping terms of 

up to 4 years. Terms of more than 2 

years are contingent upon the renewal 

of the committee by appropriate action 

prior to its expiration. 

III. Nomination Procedures 

Any interested person may nominate 

one or more qualified individuals for 

membership on the committee. Selfnominations are also accepted. 

Nominations must include a current, 

complete re ́sume ́ or curriculum vitae for 

each nominee, including current 

business address and/or home address, 

telephone number, and email address if 

available and a signed copy of the 

Acknowledgement and Consent form 

available at the FDA Advisory 

Nomination Portal (see ADDRESSES). 

Nominations must also specify the 

advisory committee for which the 

nominee is recommended. Nominations 

must also acknowledge that the 

nominee is aware of the nomination 

unless self-nominated. FDA will ask 

potential candidates to provide detailed 

information concerning such matters 

related to financial holdings, 

employment, and research grants and/or 

contracts to permit evaluation of 

possible sources of conflicts of interest. 

This notice is issued under the 

Federal Advisory Committee Act (5 

U.S.C. 1001 et seq.), and 21 CFR part 14, 

relating to advisory committees. 

Dated: December 27, 2024. 

P. Ritu Nalubola, 

Associate Commissioner for Policy. 

[FR Doc. 2025–00310 Filed 1–8–25; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Meeting of the Advisory Commission 

on Childhood Vaccines 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services. 

ACTION: Notice. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, this 

notice announces that the Advisory 

Commission on Childhood Vaccines 

(ACCV) has scheduled a public meeting. 

Information about ACCV and the agenda 

for this meeting can be found on the 

ACCV website at https://www.hrsa.gov/ 

advisory-committees/vaccines/ 

index.html. 

DATES: The ACCV meeting will be held 

on January 29, 2025, 12 p.m. eastern 

time (ET)–4 p.m. ET and January 30, 

2025, 12 p.m. ET–4 p.m. ET. 

ADDRESSES: The meeting will be held by 

Zoom webinar. For meeting information 

updates and instructions for joining 

remote meetings, go to the ACCV 

website meeting page at https://

www.hrsa.gov/advisory-committees/ 

vaccines/meetings.html. 

FOR FURTHER INFORMATION CONTACT: Pita 

Gomez, Principal Staff Liaison, Division 

of Injury Compensation Programs, 

HRSA, 5600 Fishers Lane, 8W–25A, 

Rockville, Maryland 20857; 800–338– 

2382; or ACCV@hrsa.gov. 

SUPPLEMENTARY INFORMATION: ACCV 

provides advice and recommendations 

to the Secretary of Health and Human 

Services on policy, program 

development, and other matters of 

significance related to implementation 

of the National Vaccine Injury 

Compensation Program and concerning 

other matters as described under section 

2119 of the Public Health Service Act 

(42 U.S.C. 300aa–19). 

Since priorities dictate meeting times, 

be advised that start times, end times, 

and agenda items are subject to change. 

Refer to the ACCV website listed above 

for any meeting updates that may occur. 

For the January 2025 meeting, agenda 

items may include, but are not limited 

to: updates from the Division of Injury 

Compensation Programs, Department of 

Justice, Office of Infectious Disease and 

HIV/AIDS Policy (Department of Health 

and Human Services), Immunization 

Safety Office (Centers for Disease 

Control and Prevention), National 

Institute of Allergy and Infectious 

Diseases (National Institutes of Health), 

and Center for Biologics Evaluation and 

Research (Food and Drug 

Administration). Refer to the ACCV 

website listed above for all current and 

updated information concerning the 

January 2025 ACCV meeting, including 

the draft agenda that will be posted 15 

calendar days before the meeting. 

This meeting is open to the public 

and requires registration. Registration 

details will be provided on our ACCV 

website at https://www.hrsa.gov/ 

advisory-committees/vaccines/ 

meetings.html. All registrants will be 

asked to provide their name, affiliation, 

and email address. After registration, 

individuals will receive personalized 

Zoom information via email. 

Members of the public will have the 

opportunity to provide comments. 

Public participants may submit written 

statements in advance of the meeting. 

Oral comments will be honored in the 

order they are requested and may be 

limited as time allows. Requests to 

submit a written statement or make oral 

comments to ACCV should be sent to 

Pita Gomez using the contact 

information above at least 5 business 

days before the meeting date. 

Individuals who need special 

assistance or another reasonable 

accommodation should notify Pita 

Gomez using the contact information 

listed above at least 10 business days 

before the meeting. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2025–00389 Filed 1–8–25; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of Minority Health, 

Organizational Structure 

AGENCY: Office of Minority Health, 

Office of the Secretary, Department of 

Health and Human Services. 

ACTION: Notice. 

SUMMARY: This notice provides an 

update to the organizational structure 

for the Department of Health and 

Human Services (HHS), Office of the 

Secretary (OS), Office of Minority 

Health (OMH). OMH has changed the 

name of the Division of Information and 

Education (DIE acronym), as noted in an 

April 11, 1995 Federal Register Notice, 

to the Division of Strategic 

Communication and Community 

Engagement (DCE acronym). This name 

change better aligns with the functions 

of the division and provides for a more 

socially acceptable acronym. The 

functions of the division are unchanged 

from the April 11, 1995 Federal Register 

Notice. 

SUPPLEMENTARY INFORMATION: OMH 

develops policies and programs for the 

improvement of the health status of 

racial and ethnic minority populations 

and coordinates minority health 

activities across HHS. The 

establishment of OMH is noted in 50 FR 

50847–48 (December 12, 1985). OMH’s 

organization, functions, and delegations 

of authority are noted in 60 FR 18418– 

19 (April 11, 1995), as amended in 78 

FR 59699–700 (September 27, 2013). 

This notice provides an update to Part 

A, Office of the Secretary, Statement of 

Organization, Functions, and 

Delegations of Authority for the U.S. 

Department of Health and Human 

Services at Chapter AC, to change the 

name of the OMH Division of 


khammond on DSK9W7S144PROD with NOTICES